The majority of patients suffering from multiple myelomatosis and Waldenstrom's macroglobulinaemia show disturbances in serum and urine proteins (Hobbs, 1971) . Less well established is the presence of a decreased $-lipoprotein (BLP) concentration (Burstein and Fine, 1959) . The present investigation was undertaken to examine the relationship between 'benign' paraproteinaemia, multiple myelomatosis, and Waldenstrom's macroglobulinaemia and five specific protein fractions before and after therapy. The serum proteins measured were albumin, transferrin, BLP, (Ya-antitrypsin, and 11 November 1975 Jones myelomatosis. In all patients, samples were obtained at the time of presentation, and repeatedly at intervals of 3-4 months over a period of up to 63 months.
Patients with myelomatosis were all treated with prednisolone and melphalan using the dosage regimen described by Alexanian et al (1968) , patients with Waldenstrom's macroglobulinaemia received a daily dose of chlorambucil, and those who had only a paraprotein received no specific therapy. The patients were segregated into two groups according to their responsiveness to therapy as gauged by means of criteria based upon those suggested by the Chronic Leukaemia/Multiple Myeloma Task Force of the National Cancer Institute .
Methods

SERUM IMMUNODIFFUSION STUDIES
Serum immunoglobulins G, A, and M, BLP, transferrin, al-antitrypsin, and C3 were estimated by radial immunodiffusion using a technique previously described (Shulman, 1973 2-4 ± 1-4 3-7 ± 1-3 10-3 ± 2-3 1-8 ± 0-8 31 + 6 35 ± 6 2-7 ± 0 7 0 8 ± 0-3 5 Aftertherapy 12 61 +10 2-8 + 1-3 3-7 ± 1-3 10-3 ± 2-6 2-1 + 0-6 30 + 5 29 + 12 2-7 + 07 0-8 + (table) . The nineteenth patient was suffering from Bence-Jones myelomatosis. It is also interesting to note that in seven patients the serum cholesterol was between 3-9 and 6-0 mmol/l at the time of presentation. All of them became hypercholesterolaemic (serum/cholesterol > 65 mmol/l) while on therapy, one patient reaching a level of 10-0 mmol/l. The correlation between BLP and cholesterol in the whole group was maintained while on therapy (r = 0-8872, p < 0-01).
NON-RESPONDERS AFTER THERAPY
Thirty patients (28 with myeloma; two with Waldenstrom's macroglobulinaemia) did not respond to therapy and 15 died during their first hospital admission. BLP and cholesterol values in this group of patients were significantly lower than those of normal controls (p < 0-001). Analyses were repeated when the period of follow-up, measuredfrom the time of starting treatment, lay between two and 37 months (median 10-7 months). The 15 surviving patients showed no consistent change in their BLP or cholesterol levels during the treatment period. Although there was a significant correlation between cholesterol concentration and BLP initially, this was lost after the patients had received therapy (r = 0-4215, P NS). Serum paraprotein meanlevels showed no difference in this group of patients before and after chemotherapy (table) . Of the 15 patients who were followed up, only five were still alive after 24 months.
RELATIONSHIP BETWEEN HYPOCHOLESTEROLAEMIA AND ANAEMIA
There was no significant correlation between BLP and haemoglobin concentration in our two patient groups at the time of presentation (responders r = 0-4555, P NS; non-respondersr = 0-0083,PNS)or after therapy (responders r = 0-3599, P NS; nonresponders r = 0 2200, P NS). In the analysis of the relationship between cholesterol and haemoglobin values the same pattern was found.
MEASUREMENTS OF OTHER SPECIFIC PROTEINS
Four other specific proteins, namely albumin, cxlantitrypsin, C3, and transferrin, were measured (table) . The group of patients with multiple myeloma or macroglobulinaemia had a mean transferrin level which was significantly lower and a mean aL-antitrypsin level which was significantly higher than the respective mean values in controls. C3 levels were normal in the patient groups.
Discussion
The method of radial immunodiffusion used for estimating BLP appeared to be reliable. The BLP concentration measured immunochemically was not altered by freezing the specimen or storing it at -20°C in contrast to the situation seen on electrophoresis where there is a loss of electrophoretic sharpness after freezing had taken place. Burstein and Fine (1959) first reported the presence of decreased BLP in patients with multiple myelomatosis and Waldenstrom's macroglobulinaemia. The results of the present investigation confirm their observations in untreated patients. Responsiveness to therapy was, however, accompanied by a rapid return of BLP towards normal. Patients who failed to show any biochemical or clinical improvement remained with persistently decreased BLP levels. In patients with 'benign' paraproteinaemia BLP was normal.
The reason for the relationship between progressive multiple myeloma or macroglobulinaemia and a decrease in BLP is uncertain. Although Spikes et al (1968) have suggested that the serum 'M' component in certain circumstances may interfere with the measurement of BLP, this does not appear to explain the findings in our investigation since in half the responsive patients studied, BLP concentration returned to normal at a time when the paraprotein level had not yet diminished. Furthermore, some but not all of the patients with Bence-Jones myelomatosis and pronounced hypogammaglobulinaemia showed the same pattern of response. Decreased BLP is not generally encountered in malignant neoplastic disease. In fact, increased levels have been observed in many different tumours (Kellen, 1968; Nanava and Tsintsadze, 1961) . Ohya (1960) has reported the presence of a cancer specific antigen in the BLP fraction. Further increases in the already abnormally high levels were noted with progression ofmalignancy (Barclay et al, 1956 (Barclay et al, , 1959 . A decreased BLP also does not seem to result from malnutrition. Kellen (1968) found no correlation between nutritional status or the extent of metastases and BLP. Normal levels have moreover been encountered in children suffering from protein calorie malnutrition (Shulman, 1975) .
These findings suggest that inanition is not responsible for the decreased BLP in multiple myelomatosis and Waldenstrom's macroglobulinaemia, a conclu-sion which is supported by finding normal serum albumin concentrations in most of our patients.
Hypolipidaemia, with a decrease in each of the three main plasma lipoprotein fractions, has been described in patients with chronic anaemia (Rifkind and Gale, 1967) . There was, however, no correlation between the haemoglobin level and BLP or cholesterol concentrations in our patients either before or after treatment.
The studies of the effects of steroids on plasma lipids and lipoproteins have shown conflicting results. Adlersberg et al (1950) showed a significant increase in serum cholesterol in patients receiving steroid therapy. Skanse et al (1959) furthermore showed that in short-term steroid therapy initial decrease in plasma lipids and lipoprotein levels was followed by increase affecting both triglycerides and cholesterol. However, significant increase in endogenous triglycerides in asthmatic patients receiving long-term steroid therapy was also demonstrated without changes in cholesterol levels (El-Shaboury and Hayes, 1973; Ghosh et al, 1973) . Although the presence of direct effect on BLP due solely to steroid therapy could not entirely be discounted in our cases, a rise in BLP occurred only in the responsive patients. Therefore, while the observations reported here suggest that a decrease in serum BLP concentration is associated with progressive multiple myelomatosis or macroglobulinaemia, the reason for the relationship remains obscure.
Two of the other serum protein fractions were significantly altered in our patients with multiple myelomatosis or macroglobulinaemia. Serum transferrin levels were significantly reduced and they returned towards normal in those who responded to therapy. The presence of reduced transferrin and serum iron has been reported in many chronic disorders (Cartwright and Lee, 1971) . Serum (Xl-antitrypsin levels were significantly raised before therapy in patients who were not responsive, and in both responders and non-responders after receiving therapy. The total xl-antitrypsin is one of the participants of the acute phase reaction (Larson, 1974) and its elevation was not unexpected in our patients. 
